Evotec SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVO research report →
Range $2 – $4
Price Chart
About the company
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc.
- CEO
- Christian Wojczewski
- IPO
- 2004
- Employees
- 4,553
- HQ
- Hamburg, HA, DE
Get TickerSpark's AI analysis on EVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $468.84M
- P/E
- -2.51
- Fwd P/E
- 11.59
- PEG
- 0.03
- P/S
- 0.63
- P/B
- 0.71
- EV/EBITDA
- -20.17
- Div Yield
- 0.00%
- Gross Margin
- 13.24%
- Op Margin
- -15.23%
- Net Margin
- -25.16%
- ROE
- -25.63%
- ROIC
- -8.52%
Latest fiscal year · YoY change
- Revenue
- $757.26M-5.0%
- Gross Profit
- $62.66M-45.5%
- Op Income
- $-135,312,161
- Net Income
- $-99,431,462+49.3%
- EPS
- $-0.28+49.5%
- OCF Growth
- -149.8%
- FCF Growth
- +30.9%
- 52W High
- $3.87
- 52W Low
- $1.32
- 50D MA
- $1.57
- 200D MA
- $2.38
- Beta
- 1.26
- RSI (14)
- 39
- Avg Volume
- 108.58K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Evotec said Q3 showed a clear operational inflection, with stronger D&PD execution and near break-even EBITDA, while reaffirming full-year guidance toward the upper end of the range.· November 5, 2026
- Q3 group revenue was EUR 164.9 million, broadly flat year over year, while adjusted group EBITDA improved to EUR -1.6 million from EUR -15 million.
- Nine-month revenue fell to EUR 465 million, reflecting a weak first half, slower D&PD sales-to-revenue conversion, and the prior-year Sandoz license sale.
- D&PD net sales in the base business rose 24% year over year for the first nine months, with inbound leads up more than 45% and proposal turnaround time improving about 20%.
- Vertex selected JEB for commercial manufacturing of povetacicept at Redmond, and Evotec plans to add a third manufacturing train next year.
- Management reaffirmed 2026 guidance and said revenue and adjusted EBITDA should land toward the upper end of their respective ranges.
Q3 2026 group revenue was EUR 164.9 million, versus EUR 163.9 million a year earlier; at constant exchange rates it was EUR 164.2 million. Nine-month group revenue was EUR 465 million, down 13.1% year over year from EUR 535.1 million, or down 10.8% at constant exchange rates to EUR 477.4 million. Q3 adjusted group EBITDA improved to EUR -1.6 million from EUR -15 million, while nine-month adjusted EBITDA was EUR -44.3 million versus EUR -16.9 million in the prior year period. D&PD Q3 revenue was EUR 120.1 million, down 2.3%, and JEB Q3 revenue was EUR 44.8 million, up 9.4%; D&PD nine-month revenue was EUR 348 million and JEB nine-month revenue was EUR 117.1 million. Liquidity stood at EUR 401 million at September 30, down EUR 65 million from the prior quarter. Management reaffirmed full-year 2026 guidance of EUR 570 million-EUR 610 million reported revenue, EUR 595 million-EUR 635 million constant-currency revenue, and adjusted EBITDA of minus EUR 105 million to minus EUR 70 million reported (minus EUR 90 million to minus EUR 60 million constant currency), and said both revenue and EBITDA are expected toward the upper end of the range. They also reiterated the 2030 ambition of around EUR 1 billion in revenue and adjusted EBITDA margin of 20% by end-2028, rising above 20% by end-2030.
Christian Wojczewski framed Q3 as evidence that Evotec’s transformation is starting to show through in the numbers. He emphasized stronger commercial execution in D&PD, the importance of the Vertex commercial manufacturing selection for JEB, and progress on Horizon cost savings, which he said are ahead of plan. His tone was constructive and more confident than earlier in the year, but he also repeatedly noted that the business remains in transition and that quarter-to-quarter phasing can be uneven.
Claire Hinshelwood highlighted the core financial improvements and the remaining volatility in the model. She pointed to Q3 revenue of EUR 164.9 million, adjusted EBITDA of EUR -1.6 million, and liquidity of EUR 401 million, while noting that nine-month EBITDA was still pressured by the lower revenue base and prior-year Sandoz contribution. She also said milestones contributed about EUR 30 million in Q3 and would be much lower in Q4, and emphasized capital discipline: capex has been reduced to under 10% of revenue, with 2027 capex expected to remain broadly in line with 2026 despite the Redmond third-train investment.
Analysts focused on the Q4 step-down implied by full-year guidance, the durability of JEB growth, and whether AI is producing tangible business wins. Management said Q4 will be weaker mainly because Q3 included a significant milestone contribution and because JEB revenue recognition is phasing unevenly, not because of a broad deterioration in demand. On JEB, they said the third Redmond train is not a strategy pivot back to an asset-heavy model, but a limited, necessary expansion to support Vertex and other customers, while licensing remains active. On AI, management said it is already contributing to real customer work, especially in Discovery and Cyprotex, and is helping generate leads and revenue rather than being a future-only concept.
The call showed several signs that the turnaround is taking hold: D&PD base-business net sales rose 24%, lead flow and proposal activity improved, and Q3 EBITDA got close to break-even. Management also sounded increasingly confident about Horizon savings, said Vertex has selected JEB for commercial manufacturing, and raised the visibility on a path to a more balanced and higher-margin business by 2030.
The main risk is that the nine-month numbers still show a weak first half, with revenue down 13.1% and adjusted EBITDA still deeply negative over the period. Q4 is expected to be softer because Q3 benefited from milestone revenue and profitability that will not repeat, and management acknowledged ongoing phasing variability in JEB and the broader strategic-deal pipeline. There is also execution risk around Redmond expansion, the temporary manufacturing pause in 2027, and the fact that management’s 2030 targets depend on sustained recovery in D&PD and successful commercialization of JEB.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.8%
- Shares Outstanding
- 355.18M
- Float Shares
- 336.82M
of shares held by institutions
35 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dcf Advisers, LLC | 1.05M | ▼ 30.66K |
| Optiver Holding B.V. | 62.56K | ▼ 259.59K |
| Fore Capital, LLC | 51.35K | ▲ 20.00K |
| Morgan Stanley | 32.55K | ▼ 173.22K |
| Millennium Management LLC | 26.52K | ▲ 3.68K |
| Smartharvest Portfolios, LLC | 25.17K | ▲ 25.17K |
| Old Mission Capital LLC | 22.95K | ▼ 15.08K |
| Xtx Topco Ltd | 21.69K | ▲ 3.80K |
| Squarepoint Ops LLC | 20.48K | ▲ 20.48K |
| Hrt Financial LP | 18.76K | ▲ 18.76K |
| Bnp Paribas Financial Markets | 15.90K | ▲ 2.62K |
| Virtu Financial LLC | 12.94K | ▲ 12.94K |
Held by 24 ETFs
Biggest fund positions in EVO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 22, 18 | Anderson Mark Monroe | other | 100,000 |
| Oct 22, 18 | Anderson Mark Monroe | other | 0 |
| Aug 13, 18 | Smith Scott Clifford | other | 100,000 |
| Aug 13, 18 | Smith Scott Clifford | other | 0 |
| Aug 13, 18 | LAFFER ARTHUR B | other | 100,000 |
| Aug 13, 18 | LAFFER ARTHUR B | other | 0 |
| Oct 1, 18 | QUINTON KEITH | other | 0 |
| Aug 13, 18 | Zientek Michael | other | 200,000 |
| Jul 25, 18 | Zientek Michael | other | 0 |
| Oct 1, 18 | Smith Marcus L. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVO coverage
Recent articles, reports, and earnings notes.
No research on EVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVO report →Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance
prnewswire.com · Nov 19
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
gurufocus.com · Nov 16
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
prnewswire.com · Nov 16
Evotec SE (EVO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
seekingalpha.com · Nov 6
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
businesswire.com · Nov 5
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
prnewswire.com · Nov 5
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
businesswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.